Lemalesomab: Difference between revisions
Appearance
Content deleted Content added
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Entranced98 (talk | contribs) Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound" |
||
(9 intermediate revisions by 8 users not shown) | |||
Line 1: | Line 1: | ||
⚫ | |||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| verifiedrevid = |
| verifiedrevid = 458270465 |
||
| image = |
| image = |
||
<!-- Monoclonal antibody data --> |
|||
⚫ | |||
| type = mab |
| type = mab |
||
| mab_type = mab |
| mab_type = mab |
||
| source = o |
| source = o |
||
| target = NCA-90 (granulocyte antigen) |
| target = NCA-90 (granulocyte antigen) |
||
⚫ | |||
⚫ | |||
| tradename = |
| tradename = |
||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
⚫ | |||
⚫ | |||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
⚫ | |||
⚫ | |||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = none |
||
| CAS_number_Ref = {{cascite| |
| CAS_number_Ref = {{cascite|changed|??}} |
||
| CAS_number = |
| CAS_number = 250242-54-7 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = 018649S21N |
|||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
Line 33: | Line 32: | ||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = |
||
⚫ | |||
⚫ | |||
| chemical_formula = |
| chemical_formula = |
||
| molecular_weight = |
| molecular_weight = |
||
}} |
}} |
||
'''Lemalesomab''' is a [[mouse]] [[monoclonal antibody]] for the diagnosis of inflammatory [[lesion]]s.<ref> |
'''Lemalesomab''' is a [[mouse]] [[monoclonal antibody]] for the diagnosis of inflammatory [[lesion]]s.<ref>{{cite journal | title = International Nonproprietary Names (INN) for Pharmaceutical Substances Proposed INN: List 84 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_4_2000_INN-84.pdf | journal = WHO Drug Information | volume = 14 | issue = 4 | date = 2000 | page = 260 }}</ref><ref>{{cite book | vauthors = Pelletier JP | chapter = Chapter 16 - Passive Monoclonal and Polyclonal Antibody Therapies | veditors = Maitta RW | chapter-url = https://books.google.com/books?id=4PWrDwAAQBAJ&dq=Lemalesomab&pg=PA296 | page = 296 |title=Immunologic concepts in transfusion medicine |date=2020 |publisher=Elsevier |location=Philadelphia |isbn=978-0-323-67510-9 | doi = 10.1016/B978-0-323-67509-3.00016-0 | s2cid = 213508934 }}</ref> |
||
==References== |
==References== |
||
Line 45: | Line 42: | ||
{{Monoclonals for immune system}} |
{{Monoclonals for immune system}} |
||
[[Category:Monoclonal antibodies]] |
|||
{{monoclonal-antibody-stub}} |
{{monoclonal-antibody-stub}} |
||
{{antineoplastic-drug-stub}} |
{{antineoplastic-drug-stub}} |
||
[[it:Lemalesomab]] |